The collaboration aims to replace the current, high-risk assembly process with a unified platform. By combining Applied StemCell’s specialized iPSC lines with RoosterBio’s engineered media and manufacturing expertise, the companies intend to cut development timelines and improve batch consistency. This integrated system is designed to support researchers from the initial discovery phase through to clinical-scale commercial production.
Applied StemCell and RoosterBio Partner to Streamline iPSC Production
Therapeutic developers have long struggled to piece together fragmented workflows for cell therapy manufacturing, often juggling multiple vendors for starting materials and reagents. Applied StemCell and RoosterBio are now moving to bridge this gap, launching a strategic partnership that integrates GMP-compatible iPSC technology with standardized, scalable bioprocess systems.
"ASC's collaboration with RoosterBio delivers the end-to-end bioprocessing solution that advanced therapies need to scale and reach more patients," said Dolores Baksh, CEO of Applied StemCell. Her counterpart at RoosterBio, CEO Tim Kelly, noted that the move is part of a broader push to incorporate pluripotent stem cells into their existing portfolio. For developers working in fields like immunotherapy and neurodegenerative disease, the partnership promises a reduction in technical risk and commercial uncertainty by providing a pre-validated, cohesive workflow for complex cell production.
Comments (0)
No comments yet. Be the first!